PT1250155E - Moduladores e inibidores da angiogénese e da permeabilidade vascular - Google Patents

Moduladores e inibidores da angiogénese e da permeabilidade vascular Download PDF

Info

Publication number
PT1250155E
PT1250155E PT00990365T PT00990365T PT1250155E PT 1250155 E PT1250155 E PT 1250155E PT 00990365 T PT00990365 T PT 00990365T PT 00990365 T PT00990365 T PT 00990365T PT 1250155 E PT1250155 E PT 1250155E
Authority
PT
Portugal
Prior art keywords
protein
src
modified
inhibitors
yes
Prior art date
Application number
PT00990365T
Other languages
English (en)
Inventor
David A Cheresh
Brian Eliceiri
Robert Paul
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/470,881 external-priority patent/US6685938B1/en
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PT1250155E publication Critical patent/PT1250155E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
PT00990365T 1999-12-22 2000-12-22 Moduladores e inibidores da angiogénese e da permeabilidade vascular PT1250155E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/470,881 US6685938B1 (en) 1998-05-29 1999-12-22 Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US53824800A 2000-03-29 2000-03-29

Publications (1)

Publication Number Publication Date
PT1250155E true PT1250155E (pt) 2008-06-06

Family

ID=27043259

Family Applications (2)

Application Number Title Priority Date Filing Date
PT07020078T PT1905457E (pt) 1999-12-22 2000-12-22 Composições farmacêuticas compreendendo src e/ou yes e sua utilização
PT00990365T PT1250155E (pt) 1999-12-22 2000-12-22 Moduladores e inibidores da angiogénese e da permeabilidade vascular

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT07020078T PT1905457E (pt) 1999-12-22 2000-12-22 Composições farmacêuticas compreendendo src e/ou yes e sua utilização

Country Status (19)

Country Link
EP (2) EP1250155B1 (pt)
JP (1) JP2003518077A (pt)
KR (1) KR100813818B1 (pt)
CN (1) CN1434727A (pt)
AT (2) ATE553782T1 (pt)
AU (1) AU781444B2 (pt)
BR (1) BR0016547A (pt)
CA (1) CA2395136A1 (pt)
CZ (1) CZ304320B6 (pt)
DE (1) DE60038631T2 (pt)
DK (2) DK1250155T3 (pt)
ES (2) ES2383763T3 (pt)
HU (1) HU229628B1 (pt)
NO (1) NO20023036L (pt)
PL (1) PL356815A1 (pt)
PT (2) PT1905457E (pt)
RU (1) RU2271216C2 (pt)
SK (1) SK287575B6 (pt)
WO (1) WO2001045751A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US7115651B2 (en) 2000-08-25 2006-10-03 Sloan-Kettering Institute For Cancer Research Macrocycles and uses thereof
AU2003220390A1 (en) * 2002-03-18 2003-10-08 Medtronic Ave Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis
AU2003281152A1 (en) * 2002-07-12 2004-02-02 Yihai Cao A method for inhibiting vascular permeability and tissue edema
EP1413887A1 (en) * 2002-10-22 2004-04-28 Aventis Pharma S.A. Inhibitors of Src kinase for use in Alzheimer's disease
WO2004056386A2 (en) * 2002-12-19 2004-07-08 To-Bbb Holding B.V. Nucleic acids involved in blood-brain barrier control
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
EP2233174B1 (en) * 2004-01-21 2016-07-20 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
EP1965762A1 (en) * 2005-12-23 2008-09-10 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US8404632B2 (en) * 2006-05-22 2013-03-26 The Regents Of The University Of California Compositions and methods for the delivery of nitric oxide
ATE417274T1 (de) * 2006-06-01 2008-12-15 Cellzome Ag Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
CN102656153B (zh) * 2009-10-29 2015-02-18 延世大学校产学协力团 新型血管渗漏阻断剂
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
US10293023B2 (en) 2013-03-15 2019-05-21 Children's Medical Center Corporation Method of altering vascular permeability and uses thereof
CN105311645B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用
CN105288654B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
DK0617124T3 (da) * 1990-01-26 1999-12-06 Washington Res Found Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster
EP0470569B1 (en) 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis inhibiting substance
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
CA2289102A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
CN1278724A (zh) * 1997-10-06 2001-01-03 巴斯福股份公司 抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
ATE506073T1 (de) * 1998-05-29 2011-05-15 Scripps Research Inst Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
AU1908000A (en) * 1998-11-06 2000-05-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability

Also Published As

Publication number Publication date
EP1250155A1 (en) 2002-10-23
DE60038631D1 (de) 2008-05-29
NO20023036L (no) 2002-07-22
PT1905457E (pt) 2012-05-25
HU229628B1 (en) 2014-03-28
RU2002119399A (ru) 2004-02-27
BR0016547A (pt) 2002-10-29
ES2383763T3 (es) 2012-06-26
CA2395136A1 (en) 2001-06-28
KR100813818B1 (ko) 2008-03-17
CN1434727A (zh) 2003-08-06
EP1250155B1 (en) 2008-04-16
PL356815A1 (en) 2004-07-12
ATE553782T1 (de) 2012-05-15
EP1905457B1 (en) 2012-04-18
DK1905457T3 (da) 2012-05-29
DK1250155T3 (da) 2008-08-25
HUP0203957A3 (en) 2005-07-28
SK287575B6 (sk) 2011-03-04
ES2303514T3 (es) 2008-08-16
NO20023036D0 (no) 2002-06-21
ATE392215T1 (de) 2008-05-15
JP2003518077A (ja) 2003-06-03
AU781444B2 (en) 2005-05-26
EP1250155A4 (en) 2003-08-20
DE60038631T2 (de) 2009-06-10
EP1905457A1 (en) 2008-04-02
CZ304320B6 (cs) 2014-03-05
KR20020063259A (ko) 2002-08-01
SK8492002A3 (en) 2002-11-06
HUP0203957A2 (hu) 2003-03-28
WO2001045751A1 (en) 2001-06-28
RU2271216C2 (ru) 2006-03-10
AU2740001A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
PL356815A1 (en) Angiogenesis and vascular permeability modulators and inhibitors
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
WO2002057259A3 (en) Pyrazole compounds useful as protein kinase inhibitors
WO2002048147A3 (en) Pyrazolopyridines
WO2002076976A3 (en) Rho-kinase inhibitors
WO2002076977A3 (en) Rho-kinase inhibitors
MXPA02005844A (es) Inhibidores de cinasas de proteina.
MXPA01010588A (es) Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk.
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
WO2001010894A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
HU0104085D0 (en) Method for the treatment of pulmonary hypertension
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
WO2003072541A3 (en) Chemical compounds
ZA200007321B (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src.
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
WO2001079167A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
WO2002017858A3 (en) Role of fosb in bone formation
WO2003049691A3 (en) Antisense modulation of pctaire protein kinase 1 expression
WO2001060372A3 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose